Franklin O. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Franklin O. Smith has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Gregory H. Reaman
Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Division of Oncology, Children's National Medical Center, 11 Michigan Ave, NW, Washington, DC, 20422, USA
1 shared publication R B Gerbing
Children's Oncology Group, Arcadia, CA, USA
1 shared publicationR J Arceci
The Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD, USA
1 shared publicationT A Alonzo
Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
1 shared publicationW G Woods
Children's Healthcare of Atlanta and Emory University, Atlanta, GA, USA
1 shared publicationfor the Children's Cancer Group
1 shared publication
Latest Publications
- 18 February 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (7) , 1003-1004
Why do parents engage in private cord blood banking: Fear, realistic hope or a sense of control?
- 18 February 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (7) , 1003-1004
Why do parents engage in private cord blood banking: Fear, realistic hope or a sense of control?
- 5 October 2010
- Published by Springer Nature
- p. 325-330
Future Challenges and Opportunities to Improve Outcomes for Children with Leukemia
- 5 October 2010
- Published by Springer Nature
- p. 325-330
Future Challenges and Opportunities to Improve Outcomes for Children with Leukemia
- 1 September 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (12) , 2054-2062
Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891
The Children's Cancer Group (CCG) conducted three Phase III prospective clinical trials for children with de novo acute myeloid leukemia between the years 1979 and 1995. A total of 1903 eligible children ages birth to 21 years of age were enrolled on CCG 251 (n=485), CCG 213 (n=532) and CCG 2891 (n=886). Follow-up is ongoing, with medians of 7.9, 10.9 and 8.6 years, respectively. These three clinical trials developed dose- and time-intensive induction regimens based upon high-dose cytarabine and daunomycin and randomly assigned patients to allogeneic bone marrow transplantation in first remission if an HLA-matched related donor was identified. Despite dose- and time-intensive induction regimens, remission induction rates remained relatively stable at 77–78%. However, overall survival, event-free survival and disease-free survival (DFS) increased for patients receiving intensive-timing induction therapy in comparison to patients who received standard-timing induction, regardless of the type of postremission therapy. Outcomes were best for patients receiving intensive-timing induction followed by matched related donor allogeneic transplantation with DFS of 65±9% at 6 years. These three clinical trials have established a strong foundation for the development of future studies focusing on further risk group stratification and the development of novel, molecularly-targeted therapies.
- 1 September 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (12) , 2054-2062
Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891
The Children's Cancer Group (CCG) conducted three Phase III prospective clinical trials for children with de novo acute myeloid leukemia between the years 1979 and 1995. A total of 1903 eligible children ages birth to 21 years of age were enrolled on CCG 251 (n=485), CCG 213 (n=532) and CCG 2891 (n=886). Follow-up is ongoing, with medians of 7.9, 10.9 and 8.6 years, respectively. These three clinical trials developed dose- and time-intensive induction regimens based upon high-dose cytarabine and daunomycin and randomly assigned patients to allogeneic bone marrow transplantation in first remission if an HLA-matched related donor was identified. Despite dose- and time-intensive induction regimens, remission induction rates remained relatively stable at 77–78%. However, overall survival, event-free survival and disease-free survival (DFS) increased for patients receiving intensive-timing induction therapy in comparison to patients who received standard-timing induction, regardless of the type of postremission therapy. Outcomes were best for patients receiving intensive-timing induction followed by matched related donor allogeneic transplantation with DFS of 65±9% at 6 years. These three clinical trials have established a strong foundation for the development of future studies focusing on further risk group stratification and the development of novel, molecularly-targeted therapies.